142 related articles for article (PubMed ID: 37167764)
1. Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
Schadendorf D; Tawbi H; Lipson EJ; Stephen Hodi F; Rutkowski P; Gogas H; Lao CD; Grob JJ; Moshyk A; Lord-Bessen J; Hamilton M; Guo S; Shi L; Keidel S; Long GV
Eur J Cancer; 2023 Jul; 187():164-173. PubMed ID: 37167764
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
[TBL] [Abstract][Full Text] [Related]
3. Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Diab A; Gogas H; Sandhu S; Long GV; Ascierto PA; Larkin J; Sznol M; Franke F; Ciuleanu TE; Pereira C; Muñoz Couselo E; Bronzon Damian F; Schenker M; Perfetti A; Lebbe C; Quéreux G; Meier F; Curti BD; Rojas C; Arriaga Y; Yang H; Zhou M; Ravimohan S; Statkevich P; Tagliaferri MA; Khushalani NI
J Clin Oncol; 2023 Oct; 41(30):4756-4767. PubMed ID: 37651676
[TBL] [Abstract][Full Text] [Related]
4. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
[TBL] [Abstract][Full Text] [Related]
5. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Long GV; Stephen Hodi F; Lipson EJ; Schadendorf D; Ascierto PA; Matamala L; Salman P; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; Janoski De Menezes J; Dalle S; Arance A; Grob JJ; Keidel S; Shaikh A; Sobiesk AM; Dolfi S; Tawbi HA
NEJM Evid; 2023 Apr; 2(4):EVIDoa2200239. PubMed ID: 38320023
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma.
Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L
Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis.
Rangwala HS; Fatima H; Ali M; Sunder S; Devi S; Rangwala BS; Abbas SR
J Egypt Natl Canc Inst; 2024 May; 36(1):14. PubMed ID: 38705953
[TBL] [Abstract][Full Text] [Related]
8. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
10. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV;
N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285
[TBL] [Abstract][Full Text] [Related]
11. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
Hegewisch-Becker S; Mendez G; Chao J; Nemecek R; Feeney K; Van Cutsem E; Al-Batran SE; Mansoor W; Maisey N; Pazo Cid R; Burge M; Perez-Callejo D; Hipkin RW; Mukherjee S; Lei M; Tang H; Suryawanshi S; Kelly RJ; Tebbutt NC
J Clin Oncol; 2024 Jun; 42(17):2080-2093. PubMed ID: 38723227
[TBL] [Abstract][Full Text] [Related]
12. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis.
Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F
Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ
J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Cella D; Grünwald V; Escudier B; Hammers HJ; George S; Nathan P; Grimm MO; Rini BI; Doan J; Ivanescu C; Paty J; Mekan S; Motzer RJ
Lancet Oncol; 2019 Feb; 20(2):297-310. PubMed ID: 30658932
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
18. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
20. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]